Growth in commercial AcQMap procedure volumes and associated disposable products was offset by expected declines in capital equipment sales and lower stocking orders on new console installations. This transition is aligned with the company’s intentional strategic shift to drive console utilization and optimize its installed base. Foreign exchange headwinds also accounted for about half of the year-over-year decline in reported revenue.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AFIB:
- Acutus Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Results and Appointment of Chief Financial Officer
- Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acutus Medical says AcQForce Flutter abstract accepted for presentation
- Acutus Medical Announces Acceptance of the AcQForce Flutter Abstract for Presentation during the Late-Breaking Clinical Trials and First Report Investigations sessions at the 2023 AF Symposium
- Acutus Medical Achieves EU MDR Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic
